Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection

被引：19

作者：

Pogorzelska, Joanna ^{[1
]}

Flisiak, Robert ^{[1
]}

机构：

[1] Med Univ Bialystok, Dept Infect Dis & Hepatol, 14 Zurawia St, PL-15540 Bialystok, Poland

来源：

CLINICAL AND EXPERIMENTAL HEPATOLOGY | 2016年 / 2卷 / 02期

关键词：

HCV; paritaprevir; ombitasvir; dasabuvir;

D O I：

10.5114/ceh.2016.60247

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin (OBV/PTV/r +/- DSV +/- RBV) is a new direct-acting antiviral (DAA) regimen which has improved efficacy of chronic hepatitis C virus (HCV) treatment significantly. OBV/PTV/r +/- DSV +/- RBV in clinical trials demonstrated sustained viral response (SVR) rates close to 100%. In this article we collected currently available data of 5726 patients for evaluation of OBV/PTV/r +/- DSV +/- RBV efficacy and safety in real-world experience. The sustained viral response rate in this large population was 97%, and it was exactly the same even in patients with liver cirrhotics. According to this meta-analysis, less than 3% of patients discontinued treatment due to adverse events.

引用

页码：34 / 37

页数：4

共 50 条

[1] Ombitasvir/paritaprevir/ritonavir + dasabuvir +/-ribavirin in real world hepatitis C patients
Nicole Loo
Eric Lawitz
Naim Alkhouri
Jennifer Wells
Carmen Landaverde
Angie Coste
Rossalynn Salcido
Michael Scott
Fred Poordad
World Journal of Gastroenterology, 2019, (18) : 2229 - 2239
[2] Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
Feld, Jordan J.
Bernstein, David E.
Younes, Ziad
Van Vlierberghe, Hans
Larsen, Lois
Tatsch, Fernando
Ferenci, Peter
LIVER INTERNATIONAL, 2018, 38 (09) : 1571 - 1575
[3] REAL LIFE EXPERIENCE WITH OMBITASVIR/PARITAPREVIR/RITONAVIR plus DASABUVIR AND RIBAVIRIN REGIMEN IN PATIENTS WITH COMPENSATED HCV CIRRHOSIS
Jinga, Mariana
Balaban, Vasile Daniel
Ionita-Radu, Florentina
Costache, Raluca
Nuta, Petrut
Bucurica, Sandica
Popescu, Andrada
Stoica, Victor
Vutcanu, Oana
Milicescu, Mihaela
Stefan, Ion
Macadon, Bogdan
Farcas, Alice
Naftanaila, Florica
Alexandru, Aurelia
Robu, Georgiana C.
GASTROENTEROLOGY, 2017, 152 (05) : S1148 - S1148
[4] Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study
Flisiak, R.
Janczewska, E.
Wawrzynowicz-Syczewska, M.
Jaroszewicz, J.
Zarebska-Michaluk, D.
Nazzal, K.
Bolewska, B.
Bialkowska, J.
Berak, H.
Fleischer-Stepniewska, K.
Tomasiewicz, K.
Karwowska, K.
Rostkowska, K.
Piekarska, A.
Tronina, O.
Madej, G.
Garlicki, A.
Lucejko, M.
Pisula, A.
Karpinska, E.
Kryczka, W.
Wiercinska-Drapalo, A.
Mozer-Lisewska, I.
Jablkowski, M.
Horban, A.
Knysz, B.
Tudrujek, M.
Halota, W.
Simon, K.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (09) : 946 - 956
[5] Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C
Flisiak, Robert
Flisiak-Jackiewicz, Marta
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (06) : 559 - 567
[6] Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders
Fuchs, Michael
Monto, Alexander
Brau, Norbert
Charafeddine, Mariem
Schmidt, Warren
Kozal, Michael
Naggie, Susanna
Cheung, Ramsey
Schnell, Gretja
Yu, Yao
Richards, Kristine
Mullally, Victoria
Cohen, Daniel E.
Toro, Doris
JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (12) : 3459 - 3464
[7] Real-world efficacy and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with HCV genotype 1 and 4 infection, final results of the AMBER study
Flisiak, Robert
Janczewska, Ewa
Wawrzynowicz-Syczewska, Marta
Jaroszewicz, Jerzy
Zarebska-Michaluk, Dorota
Nazzal, Khalil
Bolewska, Beata G.
Bialkowska, Jolanta
Berak, Hanna
Fleischer-Stepniewska, Katarzyna M.
Tomasiewicz, Krzysztof
Karwowska, Kornelia
Rostkowska, Karolina
Piekarska, Anna
Tronina, Olga
Madej, Grzegorz
Garlicki, Aleksander
Lucejko, Mariusz
Pisula, Arkadiusz
Karpinska, Ewa A.
Kryczka, Wieslaw
Wiercinska-Drapalo, Alicia
Mozer-Lisewska, Iwona
Jablkowski, Maciej S.
Horban, Andrzej
Knysz, Brygida
Tudrujek, Magdalena
Halota, Waldemar
Simon, Krzysztof.
HEPATOLOGY, 2016, 64 : 987A - 987A
[8] OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR TREATMENT EXPERIENCE IN HCV PATIENTS
Bayan, Kadim
Celen, Mustafa Kemal
Dal, Tuba
Ayaz, Celal
Tekin, Recep
Akdemir, Irem
Sari, Tugba
Gunal, Ozgur
Efe, Savas Cumali
ACTA MEDICA MEDITERRANEA, 2018, 34 (01): : 71 - 75
[9] Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C - a real-world study
Simon, Krzysztof Adam
Flisiak, Robert
Lapinski, Tadeusz Wojciech
Janczewska, Ewa
Wawrzynowicz-Syczewska, Marta
Jaroszewicz, Jerzy
Zarebska-Michaluk, Dorota
Nazzal, Khalil
Bolewska, Beata
Bialkowska, Jolanta
Berak, Hanna
Fleischer-Stepniewska, Katarzyna
Tomasiewicz, Krzysztof
Karwowska, Kornelia
Rostkowska, Karolina Anna
Piekarska, Anna
Tronina, Olga
Madej, Grzegorz
Garlicki, Aleksander
Lucejko, Mariusz
Pisula, Arkadiusz
Karpinska, Ewa
Kryczka, Wieslaw
Wiercinska-Drapalo, Alicja
Mozer-Lisewska, Iwona
Jablkowski, Maciej Stanislaw
Horban, Andrzej
Knysz, Brygida
Tudrujek, Magdalena
Halota, Waldemar
CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2019, 5 (03) : 215 - 223
[10] EFFICACY AND SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR, WITH OR WITHOUT RIBAVIRIN, IN PATIENTS WITH HCV GENOTYPE 4 INFECTION - REAL-WORLD EXPERIENCE FROM QATAR
Derbala, M. F.
Amer, A. M.
Alkaabi, S.
Aljyli, O.
Kamel, Y.
Sultan, K.
Elsayad, E. A.
Amin, A.
Pasic, F. I.
Elshaikh, M.
Elshaikh, M.
JOURNAL OF HEPATOLOGY, 2016, 64 : S799 - S800

← 1 2 3 4 5 →